- Home
- CGNT vs AVXL Comparison
CGNT vs AVXL Comparison
Compare CGNT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- AVXL
- Stock Information
- Founded
- CGNT 2020
- AVXL 2004
- Country
- CGNT Israel
- AVXL United States
- Employees
- CGNT N/A
- AVXL N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGNT Technology
- AVXL Health Care
- Exchange
- CGNT Nasdaq
- AVXL Nasdaq
- Market Cap
- CGNT 666.1M
- AVXL 794.0M
- IPO Year
- CGNT N/A
- AVXL N/A
- Fundamental
- Price
- CGNT $9.03
- AVXL $11.20
- Analyst Decision
- CGNT Hold
- AVXL Strong Buy
- Analyst Count
- CGNT 1
- AVXL 2
- Target Price
- CGNT N/A
- AVXL $44.00
- AVG Volume (30 Days)
- CGNT 213.3K
- AVXL 1.2M
- Earning Date
- CGNT 09-09-2025
- AVXL 08-12-2025
- Dividend Yield
- CGNT N/A
- AVXL N/A
- EPS Growth
- CGNT N/A
- AVXL N/A
- EPS
- CGNT N/A
- AVXL N/A
- Revenue
- CGNT $363,466,000.00
- AVXL N/A
- Revenue This Year
- CGNT $14.94
- AVXL N/A
- Revenue Next Year
- CGNT $9.57
- AVXL N/A
- P/E Ratio
- CGNT N/A
- AVXL N/A
- Revenue Growth
- CGNT 12.58
- AVXL N/A
- 52 Week Low
- CGNT $6.21
- AVXL $4.93
- 52 Week High
- CGNT $11.66
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- CGNT 43.27
- AVXL 53.23
- Support Level
- CGNT $9.10
- AVXL $10.93
- Resistance Level
- CGNT $9.62
- AVXL $12.68
- Average True Range (ATR)
- CGNT 0.27
- AVXL 0.84
- MACD
- CGNT 0.03
- AVXL -0.15
- Stochastic Oscillator
- CGNT 15.56
- AVXL 17.70
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.